Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... [Yahoo! Finance]
Exagen Inc. (XGN)
Last exagen inc. earnings: 3/25 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Year-to-Date Revenue: $42 million, up 8% over 2023. Gross Margin: 55.8% for Q3 2024; 59.7% excluding one-time adjustments. Year-to-Date Gross Margin: 58.7%, compared to 54.9% in 2023. Operating Expenses: $11.6 million for Q3 2024, down 9% compared to 2023. Year-to-Date Operating Expenses: $34.9 million, down 10% compared to 2023. Net Loss: $5 million for Q3 2024; $11.4 million for the first nine months of 2024, a 40% improvement over 2023. Adjusted EBITDA Loss: $4 million for Q3 2024; $7.6 million year-to-date, a 40% improvement over 2023. Cash and Cash Equivalents: $22 million at the end of Q3 2024. Accounts Receivable: $9.4 million at the end of Q3 2024, down from $11.7 million at the end of Q2. Full-Year 2024 Revenue Guidance: $55 million to $56 million. Full-Year 2024 Adjusted EBITDA Loss Guidance: Better than $12 million. Warning! GuruFocus has detected 4 Warning Signs with XGN. Release Date: November 12, 2024 For the complete transcript of the earnings
Show less
Read more
Impact Snapshot
Event Time:
XGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XGN alerts
High impacting Exagen Inc. news events
Weekly update
A roundup of the hottest topics
XGN
News
- Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics, Upcoming Webinar Hosted by XtalksPR Web
- Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform [Yahoo! Finance]Yahoo! Finance
- Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformGlobeNewswire
- Exagen Inc. to Participate in Fourth Quarter Investor ConferencesGlobeNewswire
- Exagen Inc. (NASDAQ: XGN) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
XGN
Earnings
- 11/12/24 - Beat
XGN
Sec Filings
- 11/19/24 - Form 4
- 11/18/24 - Form 4
- 11/12/24 - Form 8-K
- XGN's page on the SEC website